A LinkedIn post from SeqOne highlights a new partnership with Arquimed aimed at expanding precision medicine capabilities in Chile. The post describes Arquimed as a leader in medical innovation and indicates that the collaboration focuses on deploying SeqOne’s genomic interpretation platform to laboratories across the country.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Arquimed’s team characterizes SeqOne’s platform as clinically validated and combining automation, flexibility, and regulatory readiness. This framing suggests SeqOne is positioning its technology as suitable for clinical workflows, which may support increased adoption in regulated healthcare environments.
The LinkedIn content implies that the partnership is expected to strengthen Arquimed’s portfolio of end-to-end solutions while supporting broader access to clinical genomic data interpretation for Chilean healthcare centers. For SeqOne, deeper penetration in Latin America could expand its addressable market and diversify geographic revenue streams over time.
If the collaboration leads to increased use of SeqOne’s platform by local labs, the company could benefit from higher recurring software or service revenue and additional reference customers in the region. More broadly, the association with an established regional partner may enhance SeqOne’s competitive position in clinical genomics tools as precision medicine initiatives accelerate in emerging markets.